Chinese Hamster Ovary (CHO) cells are the most common host platform for producing antibodies. While there is widespread adoption of this platform, there remain limitations to the use of CHO cells in certain applications, in particular to produce antibodies at large scale to combat infectious diseases:
Using a C1 Protein Production Platform (a Thermophilici Filamentous Fungus Thermothelomyces heterothallica based platform), Dyadic International, Inc. demonstrated the use of a new platform for rapid engineering of product strains to produce a COVID-19 targeted antibody and a monoclonal antibody used as a standard for comparability. Dyadic benchmarked the C1 Protein Production Platform performance in comparison to CHO and other fungal expression systems in terms of speed of development and certain product quality attributes.
As part of the solution, once antibody gene sequences are received, the team:
By benchmarking the innovative, state of the art C1 Protein Production Platform versus legacy protein production methods, Dyadic discovered that the production system could potentially lead to the development of C1 based production strains for the rapid production of large quantities of lower-cost vaccine antigens and antibodies in response to pandemics and other environmental and man-made health threats.
The Thermothelomyces heterthalica C1 production system has great potential for use in responding to future pandemics because the production cell lines can be constructed quickly, and the antibodies have good productivity.
Login to the NIIMBL member portal to access more, including:
Not yet a member? Learn more about which level of NIIMBL membership is right for you and your organization.
Dyadic International Inc
